Cell and gene therapies (CGT) are widely considered a triumph of scientific innovation, focusing on providing cures for diseases rather than treatments. By 2030, it’s predicted that over 100,000 U.S. patients will utilize some form of CGT. While CGTs are revolutionary, these therapies come with a giant price tag, leaving many employers wondering how they’ll afford potential CGT use for their population.  

 

In this episode, Employers Health’s Mike Stull is joined by Drew Wilkins, managing director at Deloitte Consulting to discuss the major costs associated with CGTs, how companies can manage this costly class and how employers can prepare for its surge in the future.